We are live on ! Find out more

InfuSystem Holdings

INFU

Market cap $242M

12.15 USD

-0.10

0.82%

At close Updated Sep 15, 1:20 PM EDT

1 day

-0.82%

5 days

2.27%

1 month

-0.08%

3 months

38.07%

6 months

26.96%

Year to date

44.82%

1 year

19.59%

5 years

-9.67%

10 years

348.34%

About: InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.

Employees: 473

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

InfuSystems: More Upside Ahead

InfuSystems has shifted to a profit-focused strategy, driving a 24% FY25 adjusted EBITDA increase and maintaining strong margins despite GE contract restructuring. Wound Care revenue surged 154% due to partnerships and favorable reimbursement, while Oncology achieved record volumes and robust Patient Services growth. INFU's balance sheet remains conservative, with net debt at 0.61x EBITDA, $55.2M liquidity, and ongoing share repurchases reducing share count by 5% in H1.

InfuSystems: More Upside Ahead

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

The London Company Large Cap portfolio returned 10.9% (10.7% net) during the quarter vs. a 15.1% increase in the Russell 1000 Index. ENTG was a top contributor, benefiting from improving fab utilization and accelerating AI-driven semiconductor demand. RSG declined despite another solid quarter as softer Environmental Solutions results and continued weakness in construction-related volumes weighed on investor sentiment.

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Astrana Health outperformed as the company results have continued to demonstrate that it was not taking advantage of loopholes within Medicare coding. Magnolia Oil & Gas saw shares decline after an agreement was reached to end the war between the US and Iran and reopen the Strait of Hormuz. We initiated a position in Insteel Industries, the nation's largest manufacturer of steel wire reinforcing products for concrete construction.

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

InfuSystem Holdings, Inc. (INFU) Q2 2026 Earnings Call Transcript

InfuSystem Holdings, Inc. (INFU) Q2 2026 Earnings Call Transcript

InfuSystem Holdings, Inc. (INFU) Q2 2026 Earnings Call Transcript

Zacks Investment Research

InfuSystems Holdings, Inc. (INFU) Q2 Earnings and Revenues Surpass Estimates

InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.12 per share a year ago.

InfuSystems Holdings, Inc. (INFU) Q2 Earnings and Revenues Surpass Estimates

InfuSystem Announces Financial Results for Second Quarter 2026

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Financial Results for Second Quarter 2026.

InfuSystem Announces Financial Results for Second Quarter 2026

InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026.

InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026

Zacks Investment Research

Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?

Zacks Investment Research

InfuSystems Holdings (INFU) Soars 11.1%: Is Further Upside Left in the Stock?

InfuSystems Holdings (INFU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InfuSystems Holdings (INFU) Soars 11.1%: Is Further Upside Left in the Stock?

InfuSystem: A Good Time To Buy Before A Potential Breakout

InfuSystem is rated a buy, leveraging a stable oncology-focused patient services segment with strong FCF yields, margin progress, and reasonable valuations. INFU offers an attractive FCF yield of 11.6%, nearly double its peer Viemed Healthcare, and trades at a reasonable forward EV/EBITDA multiple below 6.5x. Management's future financial outlook is supported by reduced Capex, ERP-driven efficiencies, and growth in low-capital-intensive segments like wound care.

InfuSystem: A Good Time To Buy Before A Potential Breakout

See News Rankings

Price charts implemented using Lightweight Charts™